DKSH has broadened its collaboration with SciGen, a dynamic biopharmaceutical company founded in Singapore, to expand access and availability of its pharmaceutical products in Malaysia. Building on the successful partnership in Vietnam, DKSH will utilize its expertise and global experience to boost SciGen’s business in the Malaysian market.
Petaling Jaya, Malaysia, June 11, 2024 – DKSH Business Unit Healthcare, a leading strategic partner for companies seeking to grow their healthcare business in Asia and beyond, has successfully entered into a strategic partnership with SciGen, a rapidly growing biopharmaceutical company that markets and commercializes innovative to distribute branded pharmaceutical products and medical devices that treat endocrinological and oncological diseases worldwide. DKSH will enhance the distribution of SciGen’s distinctive products throughout Malaysia. This marks the second partnership between DKSH and SciGen, following their initial collaboration in Vietnam.
Under the agreement, DKSH will deliver sales, field marketing, distribution, logistics, as well as credit and collection. This partnership aims to leverage DKSH’s specialized expertise to enhance the availability and seamless distribution of SciGen’s high-quality products across various channels, including private and public hospitals in Malaysia. DKSH’s proficiency in market expansion services will ensure the efficient and timely distribution of SciGen’s products to pharmacies, hospitals, and healthcare providers throughout Malaysia.
Dr. Shazli Ahmed Khan, Vice President, and Head of Asia Pacific at SciGen, commented: “We are proactively exploring expansion opportunities throughout the Asian region, with a primary aim of improving access to both existing and upcoming product portfolios for patients in need. Malaysia holds strategic importance within our Asian operations, and we are dedicated to collaborating with local healthcare entities to achieve this objective, ultimately benefiting patients in Malaysia. Our commitment remains steadfast in delivering top-tier medicines and healthcare solutions to the Malaysian populace.”
Sandeep Tewari, Head Country Management and Vice President, Healthcare, DKSH Malaysia, added: “The expansion of our partnership with SciGen highlights our commitment to providing innovative and excellent healthcare. By leveraging our global expertise and local insights, we aim to enhance access to premium medications from SciGen in Malaysia. We look forward to introducing SciGen’s new products to address critical patient needs, in alignment with the government’s goals to improve healthcare access and quality.”
Together, SciGen’s products epitomize a commitment to advancing patient care, ushering in a new era of medical excellence in Malaysia. As we forge ahead with SciGen, our mission remains steadfast: to empower Malaysian patients, enriching people’s lives, ensuring healthcare for all, and redefine the boundaries of healthcare innovation.
About SciGen
SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and present commercially in all 6 continents. With the exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families. To learn more about SciGen, visit: www.scigen.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales ser-vices. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Business Unit generated net sales of CHF 5.6 bil-lion in 2023. www.dksh.com